benzoxazoles has been researched along with Cryptogenic Fibrosing Alveolitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Chen, R; Chen, S; Deng, Y; Li, D; Liu, S; Liu, Y; Lu, Y; Yu, L; Yu, X | 1 |
| Aidinis, V; Budd, DC; Kaffe, E; Müller, S; Ninou, I; Stevenson, CS; Ullmer, C | 1 |
2 other study(ies) available for benzoxazoles and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Pemafibrate attenuates pulmonary fibrosis by inhibiting myofibroblast differentiation.
Topics: Animals; Benzoxazoles; Bleomycin; Butyrates; Caspases; Fibroblasts; Idiopathic Pulmonary Fibrosis; Lung; Mice; Mice, Inbred C57BL; Myofibroblasts; NLR Family, Pyrin Domain-Containing 3 Protein; PPAR alpha; Transforming Growth Factor beta1 | 2022 |
Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Topics: Animals; Benzoxazoles; Biphenyl Compounds; Bleomycin; Idiopathic Pulmonary Fibrosis; Isoxazoles; Kaplan-Meier Estimate; Lung; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Random Allocation | 2018 |